A potential single insertion protocol for quinacrine pellet non-surgical female sterilization
Mullick, B.C.; Kessel, E.; Mumford, S.D.
Advances in Contraception the Official Journal of the Society for the Advancement of Contraception 11(3): 239-244
1995
ISSN/ISBN: 0267-4874 PMID: 8533626 DOI: 10.1007/bf01978425Document Number: 292348
Two preliminary single-insertion clinical trials of the quinacrine pellet method of non-surgical female sterilization were compared. Both trials used transcervical application of quinacrine, 252 mg, and diclofenac, 75 mg, as pellets. In the first trial (21 April 1992 to 17 February 1993), 58 women received oral contraceptives for three months. In the second trial (19 February 1993 to 25 May 1994), 229 women received medroxyprogesterone acetate, 150 mg IM, at the time of quinacrine insertion. At 18 months, the life-table pregnancy failure rate per 100 women of the first trial was 8.6 (SE 3.7), whereas the failure rate for the medroxyprogesterone acetate group was 0.5 (SE 0.5), p lt 0.05. There were no serious complications or side-effects in either group. Larger confirming trials with random allocation and long-term systematic follow-up are needed to determine whether a single injection of medroxyprogesterone improves the efficacy of quinacrine.
Document emailed within 0-6 h
